Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Tibulizumab (LY3090106) in Healthy Subjects
NCT03736772Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2018
- Primary completion
- Mar 2019
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and Sjogren's syndrome comparing LY3090106 with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Serious Adverse Events at Day 85. Started Nov 2018; status: completed.
02
Drugs
tibulizumab
03
Conditions
rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)Sjogren's syndrome
Beyond the preview
Go deeper on NCT03736772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03736772.